Search
Now showing items 1-2 of 2
Novel regulators of PD-L1 expression in cancer: CMTM6 and CMTM4-a new avenue to enhance the therapeutic benefits of immune checkpoint inhibitors.
(
AME Publishing Company
, 2017 , Article)
CMTM6 and CMTM4-a new avenue to enhance the therapeutic benefits of immune checkpoint inhibitors
Apocrine Carcinoma
(
Springer, Cham
, 2017 , Book chapter)
Carcinoma with apocrine differentiation (invasive apocrine carcinoma) is defined by “WHO Classification
of Tumours of the Breast” as “any invasive carcinoma in which cells show the cytological features of apocrine cells” ...